1. Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms

   • Sarah C. J. Jorgensen
   • Michael J. Rybak

   Editorial Open access 03 October 2018 Pages: 401 - 405

2. HIV, HCV and HBV: A Review of Parallels and Differences

   • Maria C. Leoni
   • Andrew Ustianowski
   • Joop E. Arends

   Review Open access 04 September 2018 Pages: 407 - 419

3. Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers

   • Kerstin J. Olbrich
   • Dirk Müller
   • Florian Koerber

   Review Open access 28 September 2018 Pages: 421 - 438

   

4. Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial

   • Richard G. Wunderink
   • Evangelos J. Giamarellos-Bourboulis
   • Keith S. Kaye

   Original Research Open access 01 October 2018 Pages: 439 - 455

   

5. A Markov Model to Estimate Mortality Due to HIV/AIDS Using Viral Load Levels-Based States and CD4 Cell Counts: A Principal Component Analysis Approach

   • Claris Shoko
   • Delson Chikobvu
   • Pascal O. Bessong

   Original Research Open access 02 November 2018 Pages: 457 - 471

   

6. Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials

   • Tram T. Tran
   • Darshan Mehta
   • Yuri Sanchez Gonzalez

   Original Research Open access 27 October 2018 Pages: 473 - 484

   

7. Consider Syphilis in Case of Lymphopenia in HIV-Infected Men Who Have Sex with Men (MSM): A Single-center, Retrospective Study

   • Georgios Sogkas
   • Diana Ernst
   • Matthias Stoll

   Original Research Open access 30 October 2018 Pages: 485 - 494

   

8. Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting

   • Kimberly C. Claeys
   • Evan J. Zasowski
   • Michael J. Rybak

   Original Research Open access 22 September 2018 Pages: 495 - 507

   

9. Efficacy and Safety of Tedizolid and Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Injection Drug Users: Analysis of Two Clinical Trials

   • Gregory J. Moran
   • Carisa De Anda
   • Philippe Prokocimer

   Original Research Open access 21 September 2018 Pages: 509 - 522

   

10. Prevalence of Clostridium Difficile-Associated Diarrhoea in Hospitalised Patients (Results of a Russian Prospective Multicentre Study)

    • Natalia V. Dmitrieva
    • Galina A. Klyasova
    • Stanislav V. Kazakov

    Original Research Open access 10 September 2018 Pages: 523 - 534

    

11. Comment on: ‘Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada’, Wilson et al., 22 June 2018

    • Ashleigh McGirr
    • Shehzad M. Iqbal
    • Lijoy Varghese

    Letter Open access 08 November 2018 Pages: 535 - 538

12. Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”

    • Michele R. Wilson
    • Matt Wasserman
    • Raymond Farkouh

    Letter Open access 08 November 2018 Pages: 539 - 543